Presentation is loading. Please wait.

Presentation is loading. Please wait.

Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation  Anh L. Bui, MD, Maria.

Published byMitchell Sparks Modified over 6 years ago

Similar presentations

Presentation on theme: "Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation  Anh L. Bui, MD, Maria."— Presentation transcript:

1 Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation  Anh L. Bui, MD, Maria V. Grau-Sepulveda, MD, MPH, Adrian F. Hernandez, MD, MHS, Eric D. Peterson, MD, MPH, Clyde W. Yancy, MD, Deepak L. Bhatt, MD, MPH, Gregg C. Fonarow, MD  American Heart Journal  Volume 165, Issue 4, Pages e6 (April 2013) DOI: /j.ahj Copyright © 2013 Mosby, Inc. Terms and Conditions

2 Figure In-hospital mortality for patients hospitalized with heart failure according to presenting heart rate. Loess plots showing the relationship of admission heart rate to mortality in HF patients overall (top) and dichotomized by heart rhythm (sinus rhythm versus atrial fibrillation) (bottom). Data density is shown by vertical marks. The 5th and 95th percentile heart rates are demarcated by vertical lines. American Heart Journal  , e6DOI: ( /j.ahj ) Copyright © 2013 Mosby, Inc. Terms and Conditions

3 Supplemental Figure 1 Histogram of in-hospital mortality by length of stay. American Heart Journal  , e6DOI: ( /j.ahj ) Copyright © 2013 Mosby, Inc. Terms and Conditions

4 Supplemental Figure 2 In-hospital mortality for heart failure by heart rate in various subgroups. American Heart Journal  , e6DOI: ( /j.ahj ) Copyright © 2013 Mosby, Inc. Terms and Conditions

5 Supplemental Figure 2 In-hospital mortality for heart failure by heart rate in various subgroups. American Heart Journal  , e6DOI: ( /j.ahj ) Copyright © 2013 Mosby, Inc. Terms and Conditions

6 Supplemental Figure 2 In-hospital mortality for heart failure by heart rate in various subgroups. American Heart Journal  , e6DOI: ( /j.ahj ) Copyright © 2013 Mosby, Inc. Terms and Conditions

Download ppt "Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation  Anh L. Bui, MD, Maria."

Similar presentations

Chronic Lyme Disease: A Survey of Connecticut Primary Care Physicians Michael Johnson, MD, Henry M. Feder, MD The Journal of Pediatrics Volume 157, Issue.

Chronic Lyme Disease: A Survey of Connecticut Primary Care Physicians Michael Johnson, MD, Henry M. Feder, MD The Journal of Pediatrics Volume 157, Issue.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.
Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation Nasir Shariff, MD, Ravi V. Desai, MD, Kanan Patel,

Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation Nasir Shariff, MD, Ravi V. Desai, MD, Kanan Patel,
Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal.

Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal.
Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: Data from the Mode Selection Trial (MOST)  Kirsten E. Fleischmann,

Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: Data from the Mode Selection Trial (MOST)  Kirsten E. Fleischmann,
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.
Downstream coronary effects of drug-eluting stents

Downstream coronary effects of drug-eluting stents
Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for.

Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for.
Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy.

Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy.
Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E
Force- and relaxation-frequency relations in patients with diastolic heart failure  Takashi Yamanaka, MD, Katsuya Onishi, MD, FACC, Masaki Tanabe, MD,

Force- and relaxation-frequency relations in patients with diastolic heart failure  Takashi Yamanaka, MD, Katsuya Onishi, MD, FACC, Masaki Tanabe, MD,
The outcome of primary percutaneous coronary intervention for stent thrombosis causing ST-elevation myocardial infarction  Mehmet Ergelen, MD, Sevket.

The outcome of primary percutaneous coronary intervention for stent thrombosis causing ST-elevation myocardial infarction  Mehmet Ergelen, MD, Sevket.
The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics  Cheryl Bushnell,

The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics  Cheryl Bushnell,
Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: One-year follow-up results.

Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: One-year follow-up results.
Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi- intervention in type 2 diabetes: The randomized controlled Asker.

Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi- intervention in type 2 diabetes: The randomized controlled Asker.
Rationale and design of the FreezeAF trial: A randomized controlled noninferiority trial comparing isolation of the pulmonary veins with the cryoballoon.

Rationale and design of the FreezeAF trial: A randomized controlled noninferiority trial comparing isolation of the pulmonary veins with the cryoballoon.
Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population  Richard K. Cheng, MD, MS,

Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population  Richard K. Cheng, MD, MS,
Changes in mid-life fitness predicts heart failure risk at a later age independent of interval development of cardiac and noncardiac risk factors: The.

Changes in mid-life fitness predicts heart failure risk at a later age independent of interval development of cardiac and noncardiac risk factors: The.
Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation  Hany S. Abed, BPharm, MBBS, PhD,

Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation  Hany S. Abed, BPharm, MBBS, PhD,
Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data.

Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data.

Similar presentations

Ads by Google